AGT and heart failure: Interestingly, Wieruszewski and colleagues evaluated the impact of angiotensin II among 50 patients with mechanical circulatory support (MCS) and demonstrated that among patients with cardiac failure (n = 41), angiotensin II administration was associated with 54% 28-day mortality, despite its significant impact on MAP increase [18].